|
Synonyms: VAY-736 | VAY736
Compound class:
Antibody
Comment: Ianalumab (VAY736) is an investigtional anti-BAFF receptor (TNFRSF13C) monoclonal antibody (mAb) from Novartis. BLAST analysis of peptide sequences from its INN record reveal identical matches with peptide sequences claimed in Novartis patent WO2010007082A1 [2]. The sequence matches suggest that mAb MORO7347 identified in the patent could be VAY736.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Ianalumab (VAY736) has been advanced to Phase 2 clinical trials for primary Sjögren's syndrome [1], idiopathic pulmonary fibrosis, autoimmune hepatitis, and pemphigus vulgaris, and Phase 1 for rheumatoid arthritis and CLL. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03287414 | Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis | Phase 2 Interventional | Novartis | ||
| NCT03400176 | VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib | Phase 1 Interventional | Novartis | ||
| NCT03217422 | ADCC Mediated B-Cell dEpletion and BAFF-R Blockade | Phase 2/Phase 3 Interventional | Novartis | ||
| NCT02962895 | Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS) | Phase 2 Interventional | Novartis | ||
| NCT03656562 | Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients | Phase 2 Interventional | Novartis | ||
| NCT02149420 | PD of VAY736 in Patients With Primary Sjögren's Syndrome | Phase 2 Interventional | Novartis | Results from this trial were published in 2019 [1]. These showed that a single infusion of ianalumab produced a significant and sustained depletion of B cells, which was consistent with potential clinical efficacy. The most significant benefit observed in patients who received ianalumab was a reduction in fatigue, a symptom of primary Sjögren's syndrome that is often resistant to other treatments. No major side effects were reported. | |
